Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference96 articles.
1. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study;Abida;Clin. Cancer Res.,2020
2. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration;Abida;JCO,2020
3. Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance;Afghahi;Clin. Cancer Res.,2017
4. Talapro-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC);Agarwal;JCO,2022
5. Agarwal, N., Azad, A., Carles, J., Fay, P.A., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Joung, J.Y., Fong, P.C.C., Voog, E., Jones, R.J., Shore, N.D., Dunshee, C., Zschaebitz, S., Lin, X., Healy, C.G., Di Santo, N., Zohren, F., Fizazi, K., 2023. LBA17. TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) versus Placebo (PBO) + ENZA as First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC), presented at ASCO GU 2023.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review;Journal of Oncology Pharmacy Practice;2024-08-22
2. New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2024-06
3. Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy;ACS Medicinal Chemistry Letters;2024-01-25
4. Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?;Therapeutic Advances in Medical Oncology;2024-01
5. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis;Targeted Oncology;2023-11-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3